Michel Vulfovich | PubMed Health

PubMed2005

Technology evaluation: mapatumumab, Human Genome Sciences/GlaxoSmithKline/Takeda.

Human Genome Sciences and GlaxoSmithKline, under license from Cambridge Antibody Technology, are developing mapatumumab, the intravenously administered lead from a series of human monoclonal antibody tumor necrosis factor-related apoptosis-inducing ligand receptor 1 agonists, for the potential treatment of cancer. The therapy is currently undergoing phase II clinical trials. Takeda is developing mapatumumab in Japan.

Antibodies, Monoclonal↗

PubMed2004

Molecular biological design of novel antineoplastic therapies.

Novel therapies represent a new strategy for the development of anticancer agents. New targets derived from the knowledge of the molecular structure and genetic defects has been useful in developing anticancer drugs that prolong or stabilise the progression of tumours with minimal systemic toxicities. In this review, the mechanism of action and the most significant trials regarding monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis and cyclooxygenase inhibitor-based therapies, farnesyl transferase inhibitors and proteasome inhibitors are discussed. The potential biological end points and toxicities are also described. In conclusion, novel therapies present a promising class of anticancer agents, acting through different mechanisms and offering a new perspective in the treatment of cancer.

Alkyl and Aryl Transferases↗